Clinical application of carbon nanoparticles as lymph node tracers anddrug-delivery systems in radical pulmonary carcinoma surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15007367

Enrollment

Unknown

Registered

2015-10-03

Start date

2012-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

control group:no

tracer group:Carbon nanoparticles suspension

drug-delivery group:cisplatin-activated carbon nanoparticles

Eligibility

Sex/Gender

All

Age

39 Years to 68 Years

Inclusion criteria

Inclusion criteria: Patients who undergo radical surgery for lung carcinoma in the Thoracic Surgery Department of Tumor Hospital of Yunnan Province were enrolled in the study. The diagnosis of all patients was confirmed by preoperative fine-needle aspiration cytology.

Exclusion criteria

Exclusion criteria: Patients whose diagnosis was not confirmed by preoperative fine-needle aspiration cytology,Patients with contraindication for radical surgery for lung carcinoma

Design outcomes

Primary

Measure	Time frame
the number of dissected lymph nodes;the number of lymph node metastasis;the number of lymph node apoptosis;surgery time;occurrence of adverse effects;Drainage time;Drainage volume;Lengthof surgery;Black-stained lymph nodes;	—

Countries

China

Contacts

Public ContactLincan Duan

duanmumuhuosan@163.com+86 13708454510

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026